Kaziz

About Kathryn Aziz

This author has not yet filled in any details.
So far Kathryn Aziz has created 17 blog entries.

2025 ASCO GI Cancers Symposium Trial Highlights

2025-02-03T23:19:34+00:00

Findings from CALGB/SWOG 80702 and ALTAIR studies were presented during 2025 ASCO GI Cancers Symposium, held January 23-25th.  Click on the trial titles to view full articles. CALGB/SWOG 80702 (NCT01150045) Positive ctDNA status is linked to worse DFS in stage III resected colon cancer, but celecoxib improves outcomes in ctDNA-positive patients. ctDNA status is prognostic for DFS and OS, and predictive of celecoxib benefit in the CALGB/SWOG 80702 trial. Celecoxib did not significantly affect DFS in ctDNA-negative patients, indicating its benefit is specific to ctDNA-positive individuals. Ongoing analyses aim to further elucidate ctDNA's predictive value for adjuvant FOLFOX [...]

2025 ASCO GI Cancers Symposium Trial Highlights2025-02-03T23:19:34+00:00

ASCO Daily News: GALAXY – ctDNA Negativity Linked to Improved DFS in Resectable Colorectal Cancer

2024-10-16T20:56:16+00:00

In an article, Dr. Hiroki Yukami discusses findings from the GALAXY trial presented during the 2024 ASCO Gastrointestinal Cancers Symposium. “These results show that ctDNA is a promising prognostic and predictive marker for recurrence.”—Dr. Hiroki Yukami

ASCO Daily News: GALAXY – ctDNA Negativity Linked to Improved DFS in Resectable Colorectal Cancer2024-10-16T20:56:16+00:00

ASCO Daily News: ctDNA Testing Affects Well-Being, Reducing Anxiety in Patients With CRC

2024-10-16T19:59:37+00:00

In an article, Dr. Jasenka Piljac Zegarac summarizes Dr. Pashtoon M. Kasi and colleagues' findings related to ctDNA testing and well-being in CRC patients, which were presented at the 2024 ASCO Gastrointestinal Cancers Symposium. “ctDNA should be viewed as one added (and probably one of the most powerful) tool in the toolbox instead of a standalone variable.”—Dr. Pashtoon M. Kasi

ASCO Daily News: ctDNA Testing Affects Well-Being, Reducing Anxiety in Patients With CRC2024-10-16T19:59:37+00:00

2024 ESMO Congress Meeting

2024-09-10T15:25:15+00:00

European Society For Medical Oncology (ESMO) Congress 2024 Meeting is being held Friday, September 13th through Tuesday, September 17th, with numerous sessions and posters related to minimal residual disease in colorectal cancer. Highlighted Sessions and Posters Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial Preliminary analysis in Protector-C study: A prospective, multicenter cohort of utilizing circulating tumor DNA (ctDNA) methylation as postoperative surveillance for colorectal cancer Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis [...]

2024 ESMO Congress Meeting2024-09-10T15:25:15+00:00

Cancer Network’s Around the Practice Series “ctDNA Analysis to Direct Treatment Decisions in Colorectal Cancer”

2024-05-28T17:54:44+00:00

Cancer Network posts 12-episode series titled "ctDNA Analysis to Direct Treatment Decisions in Colorectal Cancer" in which expert panelists discuss clinical trials and circulating tumor DNA's (ctDNA) role in directing treatment.

Cancer Network’s Around the Practice Series “ctDNA Analysis to Direct Treatment Decisions in Colorectal Cancer”2024-05-28T17:54:44+00:00

QUICK LINKS

MENU

© Copyright 2012 - 2025 | Avada Theme by ThemeFusion | All Rights Reserved | Powered by WordPress

Go to Top